Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucio Cocco

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Biochimica Et Biophysica Acta|September 11, 2016
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancerJames A McCubrey, Dariusz Rakus, Agnieszka Gizak, et al.
Oncotarget|June 17, 2014
GSK-3 as potential target for therapeutic intervention in cancerJames A McCubrey, Linda S Steelman, Fred E Bertrand, et al.
Leukemia|February 22, 2019
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genesMatilde Y Follo, Andrea Pellagatti, Richard N Armstrong, et al.
Oncotarget|December 22, 2016
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cellsJames A McCubrey, Timothy L Fitzgerald, Li V Yang, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Oncotarget|November 18, 2015
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signalingLaura Mediani, Federica Gibellini, Jessika Bertacchini, et al.
Oncotarget|April 28, 2015
Elevated O-GlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NF-κB signalingYong Ryoul Yang, Dae Hyun Kim, Young-Kyo Seo, et al.
Aging|June 15, 2017
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAsJames A McCubrey, Kvin Lertpiriyapong, Linda S Steelman, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Biochimica Et Biophysica Acta|September 11, 2016
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancerJames A McCubrey, Dariusz Rakus, Agnieszka Gizak, et al.
Oncotarget|June 17, 2014
GSK-3 as potential target for therapeutic intervention in cancerJames A McCubrey, Linda S Steelman, Fred E Bertrand, et al.
Leukemia|February 22, 2019
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genesMatilde Y Follo, Andrea Pellagatti, Richard N Armstrong, et al.
Oncotarget|December 22, 2016
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cellsJames A McCubrey, Timothy L Fitzgerald, Li V Yang, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Oncotarget|November 18, 2015
Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signalingLaura Mediani, Federica Gibellini, Jessika Bertacchini, et al.
Oncotarget|April 28, 2015
Elevated O-GlcNAcylation promotes colonic inflammation and tumorigenesis by modulating NF-κB signalingYong Ryoul Yang, Dae Hyun Kim, Young-Kyo Seo, et al.
Aging|June 15, 2017
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAsJames A McCubrey, Kvin Lertpiriyapong, Linda S Steelman, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Pageof 24